

## Index to CMN, Vol. 29, 2007

### Subject Index

- Actinomycetes and molecular techniques for identification, 19:148-149
- Adolescent immunization progress, 19:143-148
- human papillomavirus vaccine and, 19:146-147
- adolescent vaccination and, 19:147
- disease epidemiology and, 19:146-147
- vaccine recommendations for, 19:147
- meningococcal disease and, 19:145
- outbreaks of, 19:145
- two meningococcal vaccines and, 19:145-146
- ACIP recommendations for, 19:146
- Guillain-Barré syndrome and, 19:146
- pertussis booster and, 19:143
- pertussis infection and, 19:143-144
- adolescents and, 19:144-145
- boosting immunity in, 19:145
- incidence of, 19:144
- Antibiotic-mediated bacterial filamentation as a laboratory phenomenon, 3:22-24
- mechanism of by  $\beta$ -lactam antibiotics, 3:23, 23f
- Serratia marcescens* in burn patient and, 3:22-23, 22t, 22f
- Arbovirus infections resulting from flooding, 8:59
- Aspergillosis galactomannan antigenemia test, 1:4-5
- Bacteremia
- with *Cupriavidus pauculus*, 4:30-32
- with *Dietzia maris*, 19:148-149
- with *Micrococcus luteus*, 22:173-175
- with *Yersinia pseudotuberculosis*, 10:76-77
- Bacteroides* spp. resistance gene transfer in intestinal tract, 3:19-21
- Biliary tract infection with *Listeria monocytogenes*, 1:6-8
- Biological safety cabinets (BSC) in microbiology laboratories, 14:105-111
- as a primary engineering control (PEC), 14:105
- basic concepts of, 14:105
- cabinet classification of, 14:106-109
- Class I BSC description, 14:107
- Class II BSC description, 14:107-108
- types of, 14:107-108, 107f, 108f
- Class III BSC description, 14:108
- ensuring proper performance of, 14:109
- air balancer and, 14:111
- certification documentation for, 14:110-111
- factory/NSF testing (Annex A), 14:109
- field testing – certification (Annex F), 14:109-110
- HEPA filters and, 14:105-106
- definition of, 14:105
- penetrating particle size and, 14:106
- unidirectional airflow and, 14:106, 106f
- installation and venting considerations for, 14:108-109
- Bioterrorism agents
- Burkholderia mallei* as, 9:65
- Burkholderia pseudomallei* as, 9:65
- antimicrobial susceptibility of, 9:68
- BK virus in the transplant patient, 16:121-128
- bone marrow transplantation for, 16:125-126
- hemorrhagic cystitis and, 16:125-126
- kidney infection with, 16:122-123
- diagnosis of, 16:122-123, 125f
- pathophysiology of, 16:122
- serology of, 16:123
- urine cytology for, 16:123
- viral culture for, 16:123
- latency and reactivation in, 16:121-122
- molecular methods for, 16:123-125
- viremia and, 16:124-125
- viruria and, 16:123-124
- non-renal solid-organ transplant and, 16:126
- taxonomy and structure of, 16:121
- Blastomycosis antigen detection, 1:4
- BSC *See biological safety cabinets*
- Burkholderia cepacia*
- antimicrobial susceptibility of, 9:68
- genomovars of, 9:66, 66t
- involvement in cystic fibrosis of, 9:66
- Burkholderia pseudomallei* infections resulting from tsunamis, 8:60
- Burkholderia* spp.
- antimicrobial susceptibility of, 9:68
- as human pathogens, 9:65-67, 66t
- B. cepacia* complex as nosocomial pathogens, 9:65-66
- cystic fibrosis and, 9:66-67
- B. gladioli* in, 9:67
- B. mallei*
- as bioterrorism agent, 9:65
- as glanders agent, 9:65
- ecology of, 9:65
- genomovars of, 9:66, 66t
- nomenclature and resistance of, 9:65-69
- resistance mechanisms of, 9:67
- biofilm formation and, 9:67
- species identification of, 9:67
- use of genetic methods for, 9:67
- susceptibility testing and, 9:67-68
- synergy testing and, 9:68
- multiple combination bactericidal testing and, 9:68
- taxonomy of, 9:65
- CDC group IVc-2 *See Cupriavidus pauculus*
- Cefoxitin disk test, 5:33-40
- as surrogate for all  $\beta$ -lactam agents, 5:33
- as surrogate for oxacillin susceptibility testing, 5:33
- performance characteristics for staphylococci of, 5:34-36, 36t
- predicting *mecA*-mediated resistance in *Staphylococcus* species with, 5:33-34, 35t
- recommendations vs oxacillin for use of, 5:36
- roles of alternative tests with use of, 5:38
- mecA* PCR, 5:38
- oxacillin salt agar screen, 5:38
- PBP2a latex tests, 5:38
- quality control for, 5:39
- Cefoxitin use in selective media for MRSA, 5:38
- Cellulitis
- adjunctive measures for, 20:156
- clinical microbiology laboratory and, 20:151-158
- clinical problems of, 20:151
- diabetic foot and, 20:156
- management of, 20:156
- gram-negative bacilli and, 20:155
- immunocompromised patient and, 20:156
- S. aureus* and, 20:154
- detecting methicillin resistance and, 20:154
- antimicrobial therapy and, 20:154
- genes conferring virulence of, 20:154
- mode of spread of, 20:154-155
- MRSA carrier state and, 20:155
- toxic shock syndrome and, 20:155
- streptococci and, 20:151-154, 153f
- clinical characteristics and, 20:151-152
- necrotizing fasciitis and, 20:152
- antimicrobial therapy and, 20:152
- mixed infections and, 20:152
- recurrence and, 20:154
- serological tests for, 20:154
- specimens for, 20:152, 154
- traumatic and surgical wounds and, 20:155-156
- Cholera resulting from flooding, 8:59
- CLIA requirements
- for point-of-care testing, 23:177
- for real-time PCR, 12:87, 91-93
- CLSI
- guideline for diagnosis of mycobacterial infections (M48-P), 13:102
- method for testing *Candida* spp. (M44-A), 13:97, 99t
- new documents descriptions, 6:46-47
- guidelines for blood cultures, 6:46
- methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria (M45-A), 6:46
- methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard — 7th ed. (M11-A7), 6:47
- performance standards for antimicrobial susceptibility testing; 17th informational supplement (M100-S17), 6:46-47
- viral culture, approved guideline (M41-A), 6:45
- real-time PCR and, *See real-time PCR in clinical microbiology*
- Coccidioides immitis* outbreak after earthquake, 8:59
- Coccidioidomycosis antigen detection, 1:4
- Corneal abscess due to *Suttonella indologenes*, 18:139-142
- taxonomy of organism and, 18:140
- Cryptosporidium parvum* gastroenteritis associated with HLA-B27-negative reactive arthritis, 15:119-120
- case report of, 15:119-120
- laboratory studies in, 15:119
- treatment of, 15:119
- discussion of, 15:120
- Cupriavidus pauculus*
- antimicrobial susceptibility of, 4:30-31
- bacteremia in hemodialysis patient by, 4:30-32
- ecology of, 4:31
- infections caused by, 4:31
- microbiology of, 4:30, 31
- taxonomy of, 4:31
- Cystic fibrosis
- Burkholderia cepacia* and, 9:66
- Burkholderia gladioli* and, 9:67

- Dietzia maris*  
16S rRNA gene sequence analysis of, 19:148  
antimicrobial susceptibility of, 19:148  
bacteremia and, 19:148-149  
clinical features of, 19:148  
conventional microbiology of, 19:148  
molecular techniques for identification of, 19:148-149  
phenotypic characteristics of organism and, 19:149, 149t  
role in disease of, 19:149
- Disk diffusion method for yeasts, 13:97-102  
CLSI method for testing *Candida* spp. (M44-A), 13:97, 99t  
interpretation and reporting for, 13:99, 99t  
NeoSensitabs tablets as alternative for, 13:99-100, 98f  
procedure for, 13:98, 98f  
quality control for, 13:98-99  
ATCC strains for, 13:98, 99t  
standard medium and medium QC for, 13:97-98, 99t  
zone interpretive criteria for fluconazole and voriconazole (M44-S1), 13:97, 99t
- Empyema  
*Ralstonia pickettii* and, 7:55-56  
*Trichomonas* spp. and, 9:69-71
- Endocarditis  
*Streptococcus bovis* and, 7:49-51  
clinical diagnosis of, 7:49-50  
treatment of, 7:51
- Enterotoxigenic *Escherichia coli* infections resulting from flooding, 8:59
- Erythromycin gene transfer among intestinal anaerobes, 4:25-26
- Giardiasis resulting from flooding, 8:59
- Glanders caused by *Burkholderia mallei*, 9:65
- HEPA filters in BSC, 14:105-106
- Hepatitis A vaccine for infant immunization, 6:43-44
- Histoplasmosis antigen assays, 1:1-4
- History manipulation by microbes, 2:9-16
- Human papillomavirus  
association with cervical cancer of, 21:159-160  
HPV types and, 21:159, 160t  
detection of and utility of testing for, 21:159-167  
diagnosis of, 21:160  
conventional cytology for, 21:160, 161t  
DNA detection of, 21:160-162  
clinical utility of, 21:162-164  
testing protocols and, 21:162-164, 164f  
hybrid capture for, 21:161  
PCR for, 21:161-162  
secondary markers and, 21:164-165  
monolayer cytology for, 21:160  
natural history in men and woman of, 21:159-160  
prevention of, 21:165  
vaccine and, 21:165
- Hypocreaceae* sp. from human lung tissue, 23:180-184  
clinical report of, 23:180-181  
molecular identification of, 23:181-183, 182t, 183f  
mycological investigation of, 23:181, 181f  
susceptibility tests of, 23:183
- Trichoderma* as anamorph of, 23:180
- Immunization  
in adolescents, 19:143-148  
in infants, 6:41-45
- Infant immunization progress, 6:41-45  
hepatitis A vaccine use in, 6:42  
effect on incidence of disease and, 6:43  
maintaining herd immunity with, 6:43-44  
impact on infectious disease eradication and, 6:42t  
influenza vaccine use in, 6:42-43  
relation to morbidity and mortality in children of, 6:42-43  
needs assessment of infant hospitalization in the U.S. and, 6:41-42  
gastroenteritis and, 6:41-42  
jaundice and, 6:41,  
respiratory viruses and, 6:41  
pediatric immunization schedule and, 6:44t  
recent changes in, 6:42  
rotavirus vaccine in, 6:44-45  
new-generation vaccine (RotaTeq)  
clinical studies and, 6:44-45  
problems with early vaccine (RotaShield) and, 6:44  
viral morbidity and economic costs of, 6:44  
RSV vaccine need and, 6:42  
anti-RSV-F monoclonal antibody (palivizumab) use and, 6:42  
vaccine-preventable deaths and, 6:42t
- Influenza vaccine for infant immunization, 6:42-43
- Intestinal tract and resistance gene transfer, 3:17-21, 4:25-30  
commonality with transgenic plant food and, 3:17  
antibiotic-resistance gene uptake and, 3:17  
gram-positive anaerobes as ignored majority in, 4:25-26  
transfers with gram-negative bacteria and, 4:25-26, 26f  
erythromycin resistance genes and, 4:25-26  
problem of antibiotic use in animals, fruit trees, aquaculture and, 3:17-18  
role of bacteria in reservoir hypothesis and, 3:18, 3:18f  
conjugative transposons and, 3:19, 20, 4:26-27  
evidence for in transfer among normal intestinal microflora, 3:19-21  
*Bacteroides* spp. and, 3:3:19-20  
regulated transfer and, 4:27  
types of resistance genes among intestinal flora and, 3:19  
transfers between bacteria and human mucosal cells, 4:27-28
- Leptospirosis resulting from flooding, 8:58-59
- Listeria monocytogenes* biliary tract infection, 1:6-8  
case report of, 1:6-7  
treatment of, 1:7
- Liver disease  
*Streptococcus bovis* and, 7:52  
*magA*+ *Klebsiella pneumoniae* causing pyogenic liver abscess, 13:100-102  
K1 strain prevalence in Western and Asian countries and, 13:101-102  
*magA* gene presence in Spanish isolates and, 13:101  
method for detecting and, 13:101
- magA* virulence genes in strains and, 13:101  
association with hypermucosity phenotype and, 13:101  
association with serotype K1 and, 13:101  
proposed pathogenesis of, 13:101
- mecA*-mediated resistance detection by cefoxitin disk test, 5:33-40
- Medicare  
local coverage determinations for infectious-disease molecular diagnostics, 22:169-173  
defining forces for, 22:169, 170-172, 171f, 172f  
collaborative forces as, 22:171  
evaluative forces as, 22:171-172  
regulatory forces as, 22:170-171  
local vs. national coverage and, 22:170t  
Social Security Act and, 22:169  
determining medical necessity and, 22:169-170
- Meningococcal vaccines for adolescents, 19:145-146
- Methicillin-resistant *Staphylococcus aureus*  
cefoxitin and inducible clindamycin testing for, 18:138  
effect of inoculum density on, 18:138  
coagulase and PBP2a testing for, 18:137-138, 138f  
detection and identification from positive blood cultures of, 18:137-139, 138t  
direct susceptibility testing for, 18:139, 138t
- Microbe manipulation of human history, 2:9-16  
*C. acetobutylicum* and, 2:14-15, 2:15f  
disease and the downfall of Rome by, 2:10-11  
Napoleon and, 2:14  
nitrate fermentation and, 2:14  
Walcheren and, 2:14  
*Phytophthora infestans* and, 2:14  
plague and the Golden Age of Greece and, 2:10  
religions saved by, 2:9-10  
smallpox in the American Revolution and, 2:11-13  
yellow fever virus and, 2:13-14
- Microbes and natural disasters *See natural disasters and microbes*
- Micrococcus* spp.  
as opportunistic pathogens, 22:174  
susceptibility testing of, 22:174-175  
bacteremia with pulmonary hypertension and long-term central venous catheter, 22:173-175  
culture and identification of, 22:174  
treatment of, 22:174
- Mold contamination and hurricanes, 8:59
- MRSA infections resulting from hurricanes, 8:59
- Multiplexed suspension array technology  
detection of infectious pathogens, 11:79-86  
Luminex xMAP system for, 11:79-86  
immunoassays and, 11:80-82  
assay description of, 11:80, 81f  
biothreat agents and, 11:81  
foodborne illnesses and, 11:80  
influenza viruses and, 11:80-81  
serological applications and, 11:81-82, 81f  
instrument description and, 11:80  
nucleic acid applications of, 11:82-85, 85f

Download English Version:

<https://daneshyari.com/en/article/3345520>

Download Persian Version:

<https://daneshyari.com/article/3345520>

[Daneshyari.com](https://daneshyari.com)